Vimarsana
Biggest News Aggregation in the World

Ping Cao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ping Cao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ping Cao Today - Breaking & Trending Today

How Indiana volleyball walk-on Isa Lopez found storybook ending in Bloomington - Vimarsana News

How Indiana volleyball walk-on Isa Lopez found storybook ending in Bloomington

Indiana volleyball senior Isa Lopez gets storybook ending in Bloomington after series of setbacks nearly ended her career

Source: aol.com
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA - Vimarsana News

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA

/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with PT Kalbe Genexine Biologics ("KGbio"), an...

BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration - Vimarsana News

BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration

/PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company that uses proprietary chemoproteomics technology to discover and develop small molecules...

BridGene Biosciences to Present Data from Two Preclinical Studies at 34th EORTC-NCI-AACR Symposium 2022 - Vimarsana News

BridGene Biosciences to Present Data from Two Preclinical Studies at 34th EORTC-NCI-AACR Symposium 2022

/PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for...

BridGene raises $38.5m to develop IMTAC platform and cancer drugs - Vimarsana News

BridGene raises $38.5m to develop IMTAC platform and cancer drugs

BridGene has raised $38.5m in Series B financing round to develop its chemoproteomic platform, IMTAC, as well as oncology drugs.